| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/02/2002 | EP1165611A1 Retro-inverso prosaposin-derived peptides and use thereof |
| 01/02/2002 | EP1165610A1 Peptides useful in treating multiple sclerosis and a pharmaceutical composition comprising the same |
| 01/02/2002 | EP1165609A2 Human beta-secretase enzyme, inhibitors and their compositions and uses |
| 01/02/2002 | EP1165607A2 Protein (tp) that is involved in the development of the nervous system |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165605A1 Androgen-induced suppressor of cell proliferation and uses thereof |
| 01/02/2002 | EP1165604A2 Proteins related to neuronal regeneration and uses thereof |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165598A1 Hookworm platelet inhibitor |
| 01/02/2002 | EP1165597A1 Bifunctional molecules for delivery of therapeutics |
| 01/02/2002 | EP1165594A1 Antisense oligonucleotide modulation of stat3 expression |
| 01/02/2002 | EP1165593A1 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION |
| 01/02/2002 | EP1165591A1 47 human secreted proteins |
| 01/02/2002 | EP1165590A1 49 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165586A1 TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165493A1 Nitrogen mustard compounds and prodrugs therefor |
| 01/02/2002 | EP1165492A1 Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165184A2 Estrogen receptor-beta antagonism and bone diseases |
| 01/02/2002 | EP1165145A1 Antisense modulation of mdmx expression |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165139A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor |
| 01/02/2002 | EP1165138A1 Method for a programmed controlled ovarian stimulation protocol |
| 01/02/2002 | EP1165136A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
| 01/02/2002 | EP1165124A1 Recombinant neospora antigens and their uses |
| 01/02/2002 | EP1165122A2 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy |
| 01/02/2002 | EP1165121A2 SUPAR STIMULATING ACTIVITY OF tcuPA-MEDIATED FIBRINOLYSIS AND DIFFERENT USES THEREOF |
| 01/02/2002 | EP1165120A2 A uro-genital condition treatment system |
| 01/02/2002 | EP1165119A1 Composition based on oppositely-charged polypeptides |
| 01/02/2002 | EP1165118A2 Treatment of multiple sclerosis with a combination of interferon and growth hormone |
| 01/02/2002 | EP1165117A1 Interferon-beta use in the treatment of ewing's family of tumors |
| 01/02/2002 | EP1165116A1 Use of soluble tumor necrosis factor receptor for treating heart failure |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165112A1 Modulators of polysaccharides and uses thereof |
| 01/02/2002 | EP1165111A1 Method for pr-39 peptide regulated stimulation of angiogenesis |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165109A1 Treatment of autoimmune disease |
| 01/02/2002 | EP1165108A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 01/02/2002 | EP1165102A1 Matrix protein compositions for grafting |
| 01/02/2002 | EP1165099A2 Methods for limiting scar and adhesion formation |
| 01/02/2002 | EP1165096A2 Use of cytidine derivatives for the treatment of leukaemia |
| 01/02/2002 | EP1165093A1 Method for validating/invalidating target(s) and pathways |
| 01/02/2002 | EP1165077A2 Viral treatment |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165070A1 Thiadiazolyl urea or thiourea derivatitives for antiviral treatment |
| 01/02/2002 | EP1165059A1 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 01/02/2002 | EP1165050A1 Methods for fine powder formation |
| 01/02/2002 | EP1164992A1 Methods and compositions for enhancing fibroblast migration |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1079849B1 Use of hmg proteins for the preparation of medicaments having cytotoxic activity |
| 01/02/2002 | EP1073448B1 Fertility improving composition and application thereof |
| 01/02/2002 | EP1051157B1 Controlled release delivery of peptide or protein |
| 01/02/2002 | EP1011635A4 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 01/02/2002 | EP1005372B1 Anti-cd40l immunotoxins for the treatment of diseases |
| 01/02/2002 | EP1001801B1 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis |
| 01/02/2002 | EP0994893B1 Selective factor xa inhibitors containing a fused azepinone structure |
| 01/02/2002 | EP0941104A4 Peptide synthesis with sulfonyl protecting groups |
| 01/02/2002 | EP0877796A4 Compositions and methods for mediating cell cycle progression |
| 01/02/2002 | EP0877549A4 Methods and compositions for the reduction of xenotransplantation rejection |
| 01/02/2002 | EP0833843B1 Depigmenting activity of agouti signal protein and peptides thereof |
| 01/02/2002 | EP0822829B1 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders |
| 01/02/2002 | EP0722457B1 Compounds modifying serotoninergic transmission, diagnostic and therapeutic applications |
| 01/02/2002 | EP0671414B1 Dermatan sulfate composition as antithrombotic |
| 01/02/2002 | EP0600079B1 Oral 1alpha-hydroxyprevitamin d |
| 01/02/2002 | EP0544826B1 Superior thrombomodulin analogs for pharmaceutical use |
| 01/02/2002 | EP0472588B2 Use of alpha-d-galactosidase for the preparation of a pharmaceutical composition for reducing gastro-intestinal distress due to alpha-d-galactoside-linked sugars. |
| 01/02/2002 | CN1329669A Streptococcal C5a peptidase vaccine |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329509A Adeno-associated vectors for expression of factor VIII target cells |
| 01/02/2002 | CN1329504A F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 01/02/2002 | CN1329503A Method of treating thrombcytopenic purpura and hemolytic uremic syndrome |
| 01/02/2002 | CN1329502A Pharmaceutical compositions containing insulin |
| 01/02/2002 | CN1329501A Therapeutic agent for suppression of snoring noises |
| 01/02/2002 | CN1329500A Anti-dandruff composition comprising antifungal polypeptide |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 01/02/2002 | CN1329498A Cancer treatment composition and method using natural plant essential oils |
| 01/02/2002 | CN1329485A Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period |
| 01/02/2002 | CN1329168A A novel polypeptide-signalase 11 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329167A A novel polypeptide-human non-integral protein-metalloprotease 10.67 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329166A A novel polypeptide-human non-integral protein-metalloprotease 11.11 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329165A A novel polypeptide-human lipase 37 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329164A A novel polypeptide-acid phosphatase family protein 9 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329163A A novel polypeptide-human vacuolar proton adenosine triphosphatase C subunit 10 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329162A A novel polypeptide-human lithium sensitive 3' diphosphate nucleotidase 11.99 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329161A A novel polypeptide-serine/threonine protein kinase 11 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329160A A novel polypeptide-human mitochondrial aspartate aminotransferase 91.85 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329159A A novel polypeptide-serine/threonine protein kinase 83.05 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329158A A novel polypeptide-human alpha 2,3-sialytransferase (ST3 GalVI) 9.13 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329157A A novel polypeptide-serine/threonine protein kinase 11.22 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329156A A novel polypeptide-human mitochondrial asparatate aminotransferase 37.29 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329155A A novel polypeptide-human dynein receptor similarity kinase 51.26 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329154A A novel polypeptide-serine/threonine protein kinase 10.34 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329153A A novel polypeptide-human dehydrogenase 13 nad polynucleotide for coding this polypeptide |